title: Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
authors.affiliation: Azienda Istituti Ospitaleri di Cremona, Cremona, Italy.
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Buti
authors.forename: Maddalena
authors.initials: M
authors.lastname: Donini
authors.forename: Pietro
authors.initials: P
authors.lastname: Sergio
authors.forename: Lorella
authors.initials: L
authors.lastname: Garagnani
authors.forename: Laura
authors.initials: L
authors.lastname: Schirosi
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Passalacqua
authors.forename: Giulio
authors.initials: G
authors.lastname: Rossi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D013945:Thymoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit